What does fair value measurement disclosure mean?

This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.

King Pharmaceuticals KG Fair Value Measurement Disclosure

Fair Value Measurement Disclosure at other companies

Skyward Specialty Insurance Group, Inc.SKWD

$24.4M—

Greenlight Capital RE, Ltd.GLRE

$53.66M-16.6%

Kearny FinancialKRNY

$3.15M-37.6%

KemperKMPR

$435.6M+15.8%

Arch Capital GroupACGL

——

Reinsurance Group of AmericaRGA

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue.

The official record: King Pharmaceuticals’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's fair value measurement disclosure.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's fair value measurement disclosure?: King Pharmaceuticals (KG) reported fair value measurement disclosure of $144.31M in Q3 2025.
What does fair value measurement disclosure mean?: This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.